The Accelerated Cure Project for Multiple Sclerosis (ACP) has launched a new community-led initiative designed to ensure that people from underrepresented multiple sclerosis (MS) communities help set priorities for future MS research. sp The initiative, called Prioritized Research Agenda Development and Advancement (PRADA), creates a…
In real-world clinical practice, Ocrevus (ocrelizumab) showed sustained effectiveness in people with relapsing forms of multiple sclerosis (MS), with most patients remaining free from long-term worsening of disability over four years, according to a new study. Relapse rates and MRI disease activity were also low during follow-up. At…
Merck and Mayo Clinic have launched a research collaboration to use artificial intelligence (AI) and large-scale clinical data to accelerate drug discovery and development, with an initial focus on diseases with high unmet needs, including multiple sclerosis (MS). The partnership will combine Mayo’s extensive clinical and genomic…
Continued treatment with TG Therapeutics’ Briumvi (ublituximab) provides sustained clinical benefits for people with relapsing forms of multiple sclerosis (MS), particularly if started earlier. That’s according to data from the ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase 3 clinical trials and their ongoing open-label…
Discussion
Several (OK, many) years ago, I was having lunch with a group of fellow Green Berets when a news story appeared on the TV. The report covered a recent tragedy, and during an interview with a survivor, it was mentioned that one of the victims had not survived because they…
Get regular updates to your inbox.
